Developer docs
API playgroundTry for free, no card

Search company profiles

SFJ Pharmaceuticals

Full company profile

uuid00098mx

Namestring
SFJ Pharmaceuticals
Legal namestring
SFJ Pharmaceuticals, Inc.
Websiteurl
sfj-pharma.com
Company typeenum
Private
Founded yearint
2009
Descriptiontext

SFJ Pharmaceuticals is a privately held, Pleasanton, California-based pharmaceutical development company founded in 2009 by Robert DeBenedetto that pioneered a risk-sharing co-development business model. Rather than developing proprietary drugs, SFJ partners with pharmaceutical and biotech companies to provide 100% of late-stage (Phase 2/3) clinical development funding in exchange for success-based payments tied to regulatory approvals and commercial milestones. Partners retain full commercial rights to their assets, while SFJ assumes the development and approval risk, effectively offering non-dilutive capital alongside clinical and regulatory execution capabilities.

SFJ's service offering combines capital, expertise, and operational resources: it funds 100% of trial costs (avoiding partner equity dilution), designs and executes global clinical trials across the US, EU, Japan, and China, manages CRO relationships, and provides regulatory submission support across multiple jurisdictions. The model enables parallel trial execution, follow-on indication acceleration, and bridge funding to ex-US value inflection points. The company is backed by Blackstone Life Sciences (>$800B AUM) and Abingworth ($2.5B life science funds) as primary investors. Over its history, SFJ has completed 11 partnerships with $4.5 billion in total committed deal value, achieved 17 major market regulatory approvals, and executed 6 oncology-specific partnerships.

Notable co-developed assets include Lenvatinib (Eisai, thyroid cancer), Mylotarg and Inotuzumab (Pfizer, leukemia), Dacomitinib/Vizimpro (Pfizer, lung cancer), EMPAVELI/pegcetacoplan (Apellis, PNH), bentracimab (PhaseBio/SERB, ticagrelor reversal), BEMPEG (Nektar, head and neck cancer), and abituzumab (Merck KGaA, colorectal cancer). Revenue is generated through upfront fees, clinical milestone payments, and royalty-style success payments upon regulatory approval. The company is led by President and CEO Barbara White, MD (appointed 2024, joined as CMO in 2021), with CFO Jonathan DeBenedetto overseeing structured financing transactions exceeding $400M. SFJ operates as a private company with 11-50 employees, distributed across US headquarters and Asia-Pacific subsidiaries (SFJ Pharma Japan K.K., SFJ Pharmaceuticals Asia Pacific PTE. LTD.).

Short descriptiontext

SFJ Pharmaceuticals is a Pleasanton, CA-based private drug development company that provides 100% at-risk funding and clinical development services to pharma and biotech partners in exchange for success-based milestone payments, with 17 major market approvals across 11 partnerships.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPleasanton, United States
HQ citystring
Pleasanton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
risk-sharing drug development, clinical development funding, pharmaceutical co-development, non-dilutive financing, clinical trial partnerships
Industry3 codes
PRIMARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAKAA
Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAGACAM
Clinical Trial Financial Management & Payments (Site Budgeting)
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Pharmaceutical Drug Development Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Risk-based development funding and milestone payments
TypeProfessional Services
Description

SFJ provides 100% of clinical development funding for partner assets in exchange for success-based payments tied to regulatory approvals and commercial milestones. They assume all development and approval risk while partners retain commercial rights. Payments typically include upfront fees, clinical milestone payments, and royalty-style success payments upon approval.

sfj-pharma.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

SFJ Pharmaceuticals funds and executes late-stage (Phase 2/3) clinical development for pharmaceutical and biotechnology partners under risk-sharing co-development agreements, providing 100% of development funding and assuming full development and regulatory approval risk in exchange for upfront fees, milestone payments, and success-based payments tied to approvals. The company augments partner teams with clinical trial design, trial execution, CRO management, regulatory strategy across US/EU/Japan/China, and CMC oversight, while partners retain full commercial rights to their assets.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 17 major market regulatory approvals achieved through partnerships
+3 more records
Product overview1 text field

SFJ Pharmaceuticals operates as a global drug development company offering a unified co-development partnership platform rather than discrete software products. The core offering combines at-risk capital funding with clinical development expertise, providing non-dilutive financing and full-service trial management to pharmaceutical and biotechnology partners. Services include trial design and execution, regulatory submission support, and global market expansion expertise. SFJ has successfully co-developed multiple partnered products including Vizimpro (dacomitinib) with Pfizer, EMPAVELI (pegcetacoplan) with Apellis, bentracimab (PB2452) with PhaseBio, and BEMPEG with Nektar, among others.

Product and service5 records
1Risk-Sharing Co-Development Partnership Program
CategoryDrug Development Partnership / Co-Development Financing
Description

A B2B drug development partnership offering in which SFJ provides 100% of late-stage (Phase 2/3) clinical development funding and assumes full development and regulatory approval risk in exchange for upfront fees, milestone payments, and success-based payments tied to approvals; partners retain full commercial rights to their assets. Designed for pharmaceutical and biotech companies with late-stage pipeline assets and funding or operational gaps.

2Global Clinical Trial Design and Execution Services
CategoryClinical Operations / CRO Management
Description

End-to-end clinical trial design and execution services delivered as part of co-development partnerships, including trial design, CRO management, global multi-country trial operations, and execution oversight across US, EU, Japan, and China. Targeted at pharmaceutical and biotech partners running Phase 2/3 registrational programs.

3Global Regulatory Submission and Strategy Services
CategoryRegulatory Affairs Services
Description

Regulatory affairs services delivered as part of co-development partnerships, including submission strategy and filings across the US FDA, EU EMA, Japan PMDA, and China NMPA, supported by SFJ's SVP/Chief Regulatory Officer. Targeted at partners needing multi-market regulatory expertise alongside funding.

4Non-Dilutive Late-Stage Development Financing
CategoryDrug Development Financing
Description

Capital funding product that covers 100% of late-stage clinical trial costs for partner assets without requiring equity dilution, structured as upfront fees, clinical milestone payments, and success-based payments upon regulatory approval. Targeted at biotech and pharma partners seeking to preserve equity and avoid shareholder dilution.

5CMC and Manufacturing Supply Oversight
CategoryCMC and Manufacturing Oversight
Description

Chemistry, Manufacturing and Controls (CMC) oversight and supply assurance services delivered as part of co-development partnerships, including strategic oversight of manufacturing and analytical testing activities to support successful supply and approval of partnered medicines. Targeted at pharmaceutical and biotech partners requiring CMC leadership alongside funding.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-05-11
Description

SERB acquired exclusive US rights to bentracimab from SFJ. SFJ retained responsibility for ongoing clinical trials and BLA submission collaboration. Bentracimab BLA accepted for FDA priority review in 2024.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2021-02-17
Description

Financing and co-development collaboration for Bempegaldesleukin (BEMPEG) plus pembrolizumab in head and neck cancer. SFJ committed up to $150M funding for Phase 2/3 registrational study with success-based milestone payments over 7-8 years.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2020-01-10
Description

Financing and co-development collaboration for PB2452 (bentracimab), a reversal agent for ticagrelor. SFJ committed up to $120M in development funding and assumed central role in global clinical development outside US. Bentracimab received FDA Breakthrough Therapy Designation.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2019-02-28
Description

Novel risk-sharing collaboration for APL-2 (pegcetacoplan) development in hematologic indications including PNH. SFJ provided up to $250M in financing. First time SFJ partnered with a pre-revenue biotech company. Product received FDA approval as EMPAVELI in 2021.

5Merck KGaA (EMD Serono)
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2018-05-02
Description

Risk-sharing collaboration for abituzumab development as first-line treatment for metastatic colorectal cancer (mCRC) in combination with Erbitux and chemotherapy, targeting RAS wild-type left-sided tumors with high ανβ6 integrin expression.

sfj-pharma.com
6Eisai
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2011-01-01
Description

Collaborative development agreement for Lenvatinib (Lenvima). SFJ supported late-stage clinical development. Drug achieved multiple major market approvals (US, EU, Japan, China) for thyroid cancer.

sfj-pharma.com
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Multiple co-development partnerships including: Mylotarg (gemtuzumab ozogamicin) for AML approved 2017, Inotuzumab ozogamicin (Besponsa) for ALL approved 2017, and Dacomitinib (Vizimpro) for lung cancer approved 2018 in multiple markets.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeOthers
Description

OrbiMed is a large healthcare-dedicated investment firm that provides structured capital and company-building support to biotechs. While its core vehicles are traditional equity and credit, it competes for the same partner assets and capital allocation decisions as SFJ.

TypeDirect peer
Description

Athyrium deploys structured capital to healthcare and life sciences companies, including royalty-based and milestone-linked financing transactions that compete with SFJ's at-risk development funding model.

TypeBroad incumbent
Description

Royalty Pharma acquires royalty streams on approved and late-stage biopharma assets, competing for the same risk-adjusted cash flow that motivates SFJ's deals. It is a broader incumbent focused on post-approval and pre-approval royalty purchases rather than development operations.

TypeDirect peer
Description

Innovatus's life sciences vertical provides structured financing — including royalty and milestone-based facilities — to biopharma companies, placing it in SFJ's competitive set for development-stage risk-sharing deals.

TypeOthers
Description

Pappas Capital invests in and partners with life science companies across stages, providing both venture capital and partnership-style support. It is an adjacent investor rather than direct risk-sharing competitor but operates in the same partner-discovery ecosystem.

TypeBroad incumbent
Description

IQVIA is the largest contract research organization and has built an adjacent financial services capability that overlaps with SFJ's trial execution and financing functions, though IQVIA's primary business is service-fee CRO work rather than at-risk development financing.

TypeDirect peer
Description

HCR is the most direct analogue to SFJ's risk-sharing development-financing model. HCR purchases royalties and funds late-stage development in exchange for milestone/royalty streams — a transaction structure nearly identical to SFJ's co-development partnerships.

TypeDirect peer
Description

K2 HealthVentures provides structured debt and royalty financing to life science companies across development stages, overlapping with SFJ's risk-bearing capital solutions for late-stage programs.

TypeBroad incumbent
Description

Blackstone Life Sciences (formerly Clarus) is SFJ's primary investor and operates a parallel risk-sharing development finance franchise across larger funds and a broader set of deal structures. It shares SFJ's underlying thesis but operates at materially larger scale.

TypeDirect peer
Description

Deerfield's structured capital arm provides non-dilutive financing and operational support to clinical-stage biotechs in exchange for milestones and royalties, directly mirroring SFJ's core offering on the capital side of the deal.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SFJ Pharmaceuticals

Pharmaceutical Drug Development Servicessfj-pharma.com

SFJ Pharmaceuticals is a Pleasanton, CA-based private drug development company that provides 100% at-risk funding and clinical development services to pharma and biotech partners in exchange for success-based milestone payments, with 17 major market approvals across 11 partnerships.

What SFJ Pharmaceuticals does

SFJ Pharmaceuticals is a privately held, Pleasanton, California-based pharmaceutical development company founded in 2009 by Robert DeBenedetto that pioneered a risk-sharing co-development business model. Rather than developing proprietary drugs, SFJ partners with pharmaceutical and biotech companies to provide 100% of late-stage (Phase 2/3) clinical development funding in exchange for success-based payments tied to regulatory approvals and commercial milestones. Partners retain full commercial rights to their assets, while SFJ assumes the development and approval risk, effectively offering non-dilutive capital alongside clinical and regulatory execution capabilities.

SFJ's service offering combines capital, expertise, and operational resources: it funds 100% of trial costs (avoiding partner equity dilution), designs and executes global clinical trials across the US, EU, Japan, and China, manages CRO relationships, and provides regulatory submission support across multiple jurisdictions. The model enables parallel trial execution, follow-on indication acceleration, and bridge funding to ex-US value inflection points. The company is backed by Blackstone Life Sciences (>$800B AUM) and Abingworth ($2.5B life science funds) as primary investors. Over its history, SFJ has completed 11 partnerships with $4.5 billion in total committed deal value, achieved 17 major market regulatory approvals, and executed 6 oncology-specific partnerships.

Notable co-developed assets include Lenvatinib (Eisai, thyroid cancer), Mylotarg and Inotuzumab (Pfizer, leukemia), Dacomitinib/Vizimpro (Pfizer, lung cancer), EMPAVELI/pegcetacoplan (Apellis, PNH), bentracimab (PhaseBio/SERB, ticagrelor reversal), BEMPEG (Nektar, head and neck cancer), and abituzumab (Merck KGaA, colorectal cancer). Revenue is generated through upfront fees, clinical milestone payments, and royalty-style success payments upon regulatory approval. The company is led by President and CEO Barbara White, MD (appointed 2024, joined as CMO in 2021), with CFO Jonathan DeBenedetto overseeing structured financing transactions exceeding $400M. SFJ operates as a private company with 11-50 employees, distributed across US headquarters and Asia-Pacific subsidiaries (SFJ Pharma Japan K.K., SFJ Pharmaceuticals Asia Pacific PTE. LTD.).

SFJ Pharmaceuticals firmographics

Firmographics
Name
SFJ Pharmaceuticals
Legal name
SFJ Pharmaceuticals, Inc.
Website
https://sfj-pharma.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
11–50 employees
Short description
SFJ Pharmaceuticals is a Pleasanton, CA-based private drug development company that provides 100% at-risk funding and clinical development services to pharma and biotech partners in exchange for success-based milestone payments, with 17 major market approvals across 11 partnerships.
Ownership category
akta.pro rank

SFJ Pharmaceuticals industry classification

Industry
Product category
Pharmaceutical Drug Development Services
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAKAA
Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAGACAM
Clinical Trial Financial Management & Payments (Site Budgeting)

Keywords

  • Risk-sharing drug development
  • Clinical development funding
  • Pharmaceutical co-development
  • Non-dilutive financing
  • Clinical trial partnerships

Where SFJ Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Pleasanton
HQ country
United States
HQ region
North America

Offices1 record

Markets served

SFJ Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Risk-based development funding and milestone payments: SFJ provides 100% of clinical development funding for partner assets in exchange for success-based payments tied to regulatory approvals and commercial milestones. They assume all development and approval risk while partners retain commercial rights. Payments typically include upfront fees, clinical milestone payments, and royalty-style success payments upon approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

SFJ Pharmaceuticals product offering

Product offering

Core offering

SFJ Pharmaceuticals funds and executes late-stage (Phase 2/3) clinical development for pharmaceutical and biotechnology partners under risk-sharing co-development agreements, providing 100% of development funding and assuming full development and regulatory approval risk in exchange for upfront fees, milestone payments, and success-based payments tied to approvals. The company augments partner teams with clinical trial design, trial execution, CRO management, regulatory strategy across US/EU/Japan/China, and CMC oversight, while partners retain full commercial rights to their assets.

Product overview

SFJ Pharmaceuticals operates as a global drug development company offering a unified co-development partnership platform rather than discrete software products. The core offering combines at-risk capital funding with clinical development expertise, providing non-dilutive financing and full-service trial management to pharmaceutical and biotechnology partners. Services include trial design and execution, regulatory submission support, and global market expansion expertise. SFJ has successfully co-developed multiple partnered products including Vizimpro (dacomitinib) with Pfizer, EMPAVELI (pegcetacoplan) with Apellis, bentracimab (PB2452) with PhaseBio, and BEMPEG with Nektar, among others.

Differentiator

Problem solved

Functional benefit

Products and services

  • Risk-Sharing Co-Development Partnership Program A B2B drug development partnership offering in which SFJ provides 100% of late-stage (Phase 2/3) clinical development funding and assumes full development and regulatory approval risk in exchange for upfront fees, milestone payments, and success-based payments tied to approvals; partners retain full commercial rights to their assets. Designed for pharmaceutical and biotech companies with late-stage pipeline assets and funding or operational gaps.
  • Global Clinical Trial Design and Execution Services End-to-end clinical trial design and execution services delivered as part of co-development partnerships, including trial design, CRO management, global multi-country trial operations, and execution oversight across US, EU, Japan, and China. Targeted at pharmaceutical and biotech partners running Phase 2/3 registrational programs.
  • Global Regulatory Submission and Strategy Services Regulatory affairs services delivered as part of co-development partnerships, including submission strategy and filings across the US FDA, EU EMA, Japan PMDA, and China NMPA, supported by SFJ's SVP/Chief Regulatory Officer. Targeted at partners needing multi-market regulatory expertise alongside funding.
  • Non-Dilutive Late-Stage Development Financing Capital funding product that covers 100% of late-stage clinical trial costs for partner assets without requiring equity dilution, structured as upfront fees, clinical milestone payments, and success-based payments upon regulatory approval. Targeted at biotech and pharma partners seeking to preserve equity and avoid shareholder dilution.
  • CMC and Manufacturing Supply Oversight Chemistry, Manufacturing and Controls (CMC) oversight and supply assurance services delivered as part of co-development partnerships, including strategic oversight of manufacturing and analytical testing activities to support successful supply and approval of partnered medicines. Targeted at pharmaceutical and biotech partners requiring CMC leadership alongside funding.

Quantifiable outcome

  • 17 major market regulatory approvals achieved through partnerships
  • +3 more outcomes

Companies that use SFJ Pharmaceuticals

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles2 records

SFJ Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

SFJ Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered major and flagship.

  • SERB PharmaceuticalsmajorStrategic or Co-development Partner · 11 May 2023SERB acquired exclusive US rights to bentracimab from SFJ. SFJ retained responsibility for ongoing clinical trials and BLA submission collaboration. Bentracimab BLA accepted for FDA priority review in 2024.
  • Nektar TherapeuticsmajorStrategic or Co-development Partner · 17 February 2021Financing and co-development collaboration for Bempegaldesleukin (BEMPEG) plus pembrolizumab in head and neck cancer. SFJ committed up to $150M funding for Phase 2/3 registrational study with success-based milestone payments over 7-8 years.
  • PhaseBio PharmaceuticalsflagshipStrategic or Co-development Partner · 10 January 2020Financing and co-development collaboration for PB2452 (bentracimab), a reversal agent for ticagrelor. SFJ committed up to $120M in development funding and assumed central role in global clinical development outside US. Bentracimab received FDA Breakthrough Therapy Designation.
  • Apellis PharmaceuticalsflagshipStrategic or Co-development Partner · 28 February 2019Novel risk-sharing collaboration for APL-2 (pegcetacoplan) development in hematologic indications including PNH. SFJ provided up to $250M in financing. First time SFJ partnered with a pre-revenue biotech company. Product received FDA approval as EMPAVELI in 2021.
  • Merck KGaA (EMD Serono)majorStrategic or Co-development Partner · 2 May 2018Risk-sharing collaboration for abituzumab development as first-line treatment for metastatic colorectal cancer (mCRC) in combination with Erbitux and chemotherapy, targeting RAS wild-type left-sided tumors with high ανβ6 integrin expression.
  • EisaiflagshipStrategic or Co-development Partner · 1 January 2011Collaborative development agreement for Lenvatinib (Lenvima). SFJ supported late-stage clinical development. Drug achieved multiple major market approvals (US, EU, Japan, China) for thyroid cancer.
  • PfizerflagshipStrategic or Co-development PartnerMultiple co-development partnerships including: Mylotarg (gemtuzumab ozogamicin) for AML approved 2017, Inotuzumab ozogamicin (Besponsa) for ALL approved 2017, and Dacomitinib (Vizimpro) for lung cancer approved 2018 in multiple markets.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

SFJ Pharmaceuticals competitors and assessment

Company assessment

Others

  • OrbiMed: OrbiMed is a large healthcare-dedicated investment firm that provides structured capital and company-building support to biotechs. While its core vehicles are traditional equity and credit, it competes for the same partner assets and capital allocation decisions as SFJ.
  • Pappas Capital: Pappas Capital invests in and partners with life science companies across stages, providing both venture capital and partnership-style support. It is an adjacent investor rather than direct risk-sharing competitor but operates in the same partner-discovery ecosystem.

Direct peers

  • Athyrium Capital Management: Athyrium deploys structured capital to healthcare and life sciences companies, including royalty-based and milestone-linked financing transactions that compete with SFJ's at-risk development funding model.
  • Innovatus Capital Partners: Innovatus's life sciences vertical provides structured financing — including royalty and milestone-based facilities — to biopharma companies, placing it in SFJ's competitive set for development-stage risk-sharing deals.
  • HealthCare Royalty Partners (HCR): HCR is the most direct analogue to SFJ's risk-sharing development-financing model. HCR purchases royalties and funds late-stage development in exchange for milestone/royalty streams — a transaction structure nearly identical to SFJ's co-development partnerships.
  • K2 HealthVentures: K2 HealthVentures provides structured debt and royalty financing to life science companies across development stages, overlapping with SFJ's risk-bearing capital solutions for late-stage programs.
  • Deerfield Management: Deerfield's structured capital arm provides non-dilutive financing and operational support to clinical-stage biotechs in exchange for milestones and royalties, directly mirroring SFJ's core offering on the capital side of the deal.

Broad incumbents

  • Royalty Pharma: Royalty Pharma acquires royalty streams on approved and late-stage biopharma assets, competing for the same risk-adjusted cash flow that motivates SFJ's deals. It is a broader incumbent focused on post-approval and pre-approval royalty purchases rather than development operations.
  • IQVIA: IQVIA is the largest contract research organization and has built an adjacent financial services capability that overlaps with SFJ's trial execution and financing functions, though IQVIA's primary business is service-fee CRO work rather than at-risk development financing.
  • Blackstone Life Sciences: Blackstone Life Sciences (formerly Clarus) is SFJ's primary investor and operates a parallel risk-sharing development finance franchise across larger funds and a broader set of deal structures. It shares SFJ's underlying thesis but operates at materially larger scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

SFJ Pharmaceuticals social profiles

Digital presence

SFJ Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SFJ Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles8 records

SFJ Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SFJ Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SFJ Pharmaceuticals

What does SFJ Pharmaceuticals do?

SFJ Pharmaceuticals funds and executes late-stage (Phase 2/3) clinical development for pharmaceutical and biotechnology partners under risk-sharing co-development agreements, providing 100% of development funding and assuming full development and regulatory approval risk in exchange for upfront fees, milestone payments, and success-based payments tied to approvals. The company augments partner teams with clinical trial design, trial execution, CRO management, regulatory strategy across US/EU/Japan/China, and CMC oversight, while partners retain full commercial rights to their assets.

Is SFJ Pharmaceuticals a public or private company?

SFJ Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.

When was SFJ Pharmaceuticals founded?

SFJ Pharmaceuticals was founded in 2009. It employs 11 to 50 people.

Where is SFJ Pharmaceuticals based?

SFJ Pharmaceuticals is headquartered in Pleasanton, United States, in the North America region.

How does SFJ Pharmaceuticals make money?

One revenue line is on record: risk-based development funding and milestone payments.

Who are SFJ Pharmaceuticals's main competitors?

Others on record are OrbiMed and Pappas Capital. Direct peers are Athyrium Capital Management, Innovatus Capital Partners, HealthCare Royalty Partners (HCR), K2 HealthVentures and Deerfield Management. Broad incumbents are Royalty Pharma, IQVIA and Blackstone Life Sciences.

Does SFJ Pharmaceuticals have an API?

No public API is recorded for SFJ Pharmaceuticals.

What industry is SFJ Pharmaceuticals in?

SFJ Pharmaceuticals's product category is Pharmaceutical Drug Development Services. Its primary akta.pro industry code is HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution), with a secondary code of HLAGAKAA, Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AJMCTicagrelor Antidote Bentracimab Safely Reverses Antiplatelet Effects in Phase 3 REVERSE-IT TrialPhaseBio Pharmaceuticals and SFJ Pharma presented late-breaking results from the phase 3 REVERSE-IT trial, demonstrating that their investigational antidote bentracimab safely and effectively reverses the antiplatelet effects of ticagrelor. The study showed that 94.3% of patients achieved normal blood clotting within minutes of infusion, with high rates of hemostasis in those undergoing urgent surgery or experiencing major bleeding. These positive findings support the ongoing regulatory assessment for FDA approval, following recent orphan drug designation.HCP LiveREVERSE-IT: Bentracimab Effective in Reversing Ticagrelor Antiplatelet EffectsData from the REVERSE-IT trial presented at the ACC 2025 Annual Scientific Sessions demonstrate that bentracimab effectively and rapidly reverses the antiplatelet effects of ticagrelor, restoring normal clotting within minutes. The drug was developed by SFJ Pharmaceuticals and is set for US commercialization by SERB Pharmaceuticals, with an application currently under FDA review. This development addresses a critical clinical need for managing life-threatening bleeding or facilitating urgent surgery in patients taking ticagrelor.GlobeNewswireSFJ Pharmaceuticals & SERB Pharmaceuticals Present Positive Final Results from Pivotal Ph 3 REVERSE-IT Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ticagrelor in Patients RequiringSFJ and SERB announced final Phase 3 REVERSE-IT trial results showing bentracimab rapidly reversed ticagrelor's antiplatelet effects in patients needing urgent surgery or major bleeding. The trial achieved its primary endpoint, with platelet function restored within 5-10 minutes and maintained throughout the 16-hour infusion. The drug was well tolerated with no serious adverse reactions.Pharmaceutical TechnologyFDA accepts SFJ and SERB's bentracimab BLA for priority reviewThe US Food and Drug Administration has accepted the biologics licence application for bentracimab, a reversal agent for ticagrelor, from SFJ Pharmaceuticals and SERB Pharmaceuticals for priority review. The regulatory decision is expected in the first quarter of 2025, based on data from the Phase III REVERSE-IT trial. Bentracimab aims to provide hospitals with a solution to reverse antiplatelet effects during surgeries or major bleeding events.FierceBiotechGoldilocks and the 'not great, but good enough': Drug development shops offer 'sweet spot' deal alternativeBiopharma companies are using a 'Goldilocks' deal strategy to offload second-tier drug assets to specialized firms like Avillion and SFJ Pharma, which cover 100% of development costs in exchange for exclusive IP and financial returns. The arrangement lets partners retain commercial rights while reducing financial burden, though such deals are uncommon due to the need for a 'sweet spot' success probability.Pharmaceutical TechnologySERB Pharmaceuticals buys US rights for bentracimab from SFJSERB Pharmaceuticals has acquired exclusive US rights for bentracimab from SFJ Pharmaceuticals, with the latter leading ongoing clinical trials and both entities collaborating to file a biologics licence application with the FDA later this year. Bentracimab is a monoclonal antibody fragment designed to reverse the antiplatelet activity of ticagrelor, marketed as Brilinta by AstraZeneca. The drug received breakthrough therapy designation from the US FDA in 2019 and showed positive results in interim Phase III trial analyses.GlobeNewswireSERB Pharmaceuticals and SFJ Pharmaceuticals announce a U.S. partnership for bentracimab, a ticagrelor reversal agentSERB Pharmaceuticals acquired exclusive US rights to bentracimab, a ticagrelor reversal agent, from SFJ Pharmaceuticals. The companies expect to file a Biologics License Application with the FDA later this year. The drug has already received FDA Breakthrough Therapy Designation.American City Business JournalsPhaseBio reaches a deal to transfer its assets to SFJ Pharmaceuticals for $32.9MPhaseBio agreed to transfer its assets to SFJ Pharmaceuticals for $32.9 million. The deal includes all program assets for its new drug candidate in late-stage testing, intended to reverse potentially adverse effects of blood-thinning medicine.BenzingaPhaseBio Might Have To Return Global Rights To Its Lead ProgramPhaseBio Pharmaceuticals received notice that its co-development partner SFJ Pharmaceuticals Group elected to transfer bentracimab rights to SFJ after PhaseBio failed to remedy its Going Concern Condition. The company had received acquisition offers for the drug candidate but could not proceed due to SFJ requiring PhaseBio to refrain from terminating the agreement and asserting accelerated termination payment obligations. PhaseBio shares dropped 47.37% in pre-market trading following the announcement.BioSpacePhaseBio Pharmaceuticals and SFJ Pharmaceuticals® Announce Approval of IND Application in China for BentracimabPhaseBio Pharmaceuticals and SFJ Pharmaceuticals received approval of the IND application for bentracimab from China's NMPA. The approval enables enrollment in the REVERSE-IT Phase 3 trial in China, with first patients expected later in 2021. PhaseBio retains commercial rights in China and is seeking licensing partners.